

# Pulmonary Tuberculosis and Diabetes Comorbidity is Associated with Heightened Systemic Th1, Th17, Treg Cytokines and Others Biochemical Parameters

Leonard SAMA<sup>1</sup>, Thibau Tchouangueu<sup>1</sup>, Omer Ngouateu<sup>2</sup>, Mbuli Ali<sup>3</sup>, Solomon Tchuandom<sup>1</sup>, Ousenu Karimo<sup>1</sup>, and Christopher Tume<sup>4</sup>

<sup>1</sup>University of Dschang Department of Biochemistry

<sup>2</sup>University of Yaounde 1 Faculty of Sciences

<sup>3</sup>University of Dschang Faculty of Sciences

<sup>4</sup>University of Dschang

April 05, 2024

## Abstract

**Background:** This study aims to evaluate the impact of type 2 diabetes on pulmonary tuberculosis immune response. **Methods:** The tuberculosis diagnosis was based on the sputum smear and positivity of culture, whereas type 2 diabetes was diagnosis based on fasting blood sugar, 2-h PG, and glycated haemoglobin. Standardized techniques were used to obtain liver enzymes and lipid profiles whereas ELISA cytokine assay system was used to measured plasma cytokines levels. **Results:** fasting blood glucose ( $p < 0.0001$ ), 2hPG ( $p = 0.0097$ ) and Glycated haemoglobin percentage ( $p < 0.0001$ ) in TB patients with diabetes were found to be significantly high as compare with TB patients without diabetes. While total cholesterol ( $p = 0.0093$ ), serum triglycerides ( $p = 0.0001$ ) and low-density lipoprotein cholesterol ( $p = 0.0086$ ), were significantly high among Tb with diabetes, whereas High density lipoprotein cholesterol found to be significantly ( $p = 0.0002$ ) elevated among TB patients without diabetes. TB and diabetes linked with increase concentration of Th1 (IFN- $\gamma$  and TNF- $\alpha$ ), Th17 (IL-17A) and Treg cytokines. The systemic levels of analysed cytokines show a positive increase associated with the HbA1c levels among TB patients except with IL-6 where there was no association with glycated haemoglobin. A significantly increased association was found between IL-22 and IFN- $\gamma$  plasmatic levels. **Conclusion:** Our study shows an increase in characterized TB diabetics patients in cytokine response, signaling that type 2 diabetes potentially participate in chronic inflammation that increases pathology and low control of tuberculosis.

## Pulmonary Tuberculosis and Diabetes Comorbidity is Associated with Heightened Systemic Th1, Th17, Treg Cytokines and Others Biochemical Parameters

Leonard Fonkeng Sama<sup>1\*</sup>, Thibau Flaurant Tchouangueu<sup>1</sup>, Omer Bebe Ngouateu<sup>2</sup>, Innocent Mbuli Ali<sup>1</sup>, Salomon Bonsi Tchuandom<sup>1</sup>, Ousenu Karimo<sup>1</sup> and Christopher B. Tume<sup>1,3</sup>

<sup>1</sup> Research Unit of Microbiology and Antimicrobial Substances, Department of Biochemistry, University of Dschang, P.O Box 67 Dschang-Cameroon

<sup>2</sup>University of Yaoundé I, Faculty of Science, Department of Animal Biology and Physiology, P.O. Box 812-Yaoundé-Cameroon

<sup>3</sup>University of Bamenda, Faculty of Science, Department of Biochemistry, University of Bamenda, Cameroon

**Corresponding authors:**

\*Leonard Fonkeng Sama: *safrole2000@yahoo.fr*

Other authors e-mails:

Thibau Flaurant Tchouangueu: *ttchouangueu@gmail.com*

Omer Bebe Ngouateu: *ob\_ngouateu@yahoo.fr*

Innocent Mbuli Ali : *dr.alinn@gmail.com*

Salomon Bonsi Tchuandom: *tbonshi@yahoo.fr*

Ousenu Karimo: *ousenukarimo90@gmail.com*

Christopher B. Tume : *tumechrist@yahoo.com*

**Keys words** , Tuberculosis, cytokines, type 2 diabetes

**Abbreviation:** interferon- $\gamma$  (IFN- $\gamma$ ), interleukin (IL), Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), Type 1 (Th1); Regulatory T-cells (Treg), Type 17 (Th17), 2hours plasma glucose (2hPG), American Diabetes Association (ADA), pulmonary tuberculosis (TB), glycated hemoglobin (HbA1c), Tuberculosis with diabetes mellitus (TB-DM); Tuberculosis without diabetes mellitus (TB-NDM), Random blood sugar (RBS), Cameroon Bioethics Initiative (CMBIN), natural killer (NK), natural killer T (NKT), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma glutamyltransferase ( $\delta$ GT) and Alanine aminotransferase (ALP)

## ABSTRACT

**Background:** This study aims to evaluate the impact of type 2 diabetes on pulmonary tuberculosis immune response. **Methods:** The tuberculosis diagnosis was based on the sputum smear and positivity of culture, whereas type 2 diabetes was diagnosis based on fasting blood sugar, 2-h PG, and glycated haemoglobin. Standardized techniques were used to obtain liver enzymes and lipid profiles whereas ELISA cytokine assay system was used to measured plasma cytokines levels. **Results:** fasting blood glucose ( $p < 0.0001$ ), 2hPG ( $p = 0.0097$ ) and Glycated haemoglobin percentage ( $p < 0.0001$ ) in TB patients with diabetes were found to be significantly high as compare with TB patients without diabetes. While total cholesterol ( $p = 0.0093$ ), serum triglycerides ( $p = 0.0001$ ) and low-density lipoprotein cholesterol ( $p = 0.0086$ ), were significantly high among Tb with diabetes, whereas High density lipoprotein cholesterol found to be significantly ( $p = 0.0002$ ) elevated among TB patients without diabetes. TB and diabetes linked with increase concentration of Th1 (IFN- $\gamma$  and TNF- $\alpha$ ), Th17 (IL-17A) and Treg cytokines. The systemic levels of analysed cytokines show a positive increase associated with the HbA1c levels among TB patients except with IL-6 where there was no association with glycated haemoglobin. A significantly increased association was found between IL-22 and IFN- $\gamma$  plasmatic levels. **Conclusion:** Our study shows an increase in characterized TB diabetics patients in cytokine response, signaling that type 2 diabetes potentially participate in chronic inflammation that increases pathology and low control of tuberculosis.

## INTRODUCTION

Despite the improvement in tuberculosis (TB) therapy, the disease remains responsible for 2-3 million deaths annually worldwide. Its association with type 2 diabetes mellites is evident and has been recognized for centuries. It has been proven that, diabetes mellites is a leding cause of tuberculosis and it can felt the paqpect and medication outcome of the disease [1]. Several authors show the relative risk of diabetic patients to develop tuberculosis range from 2.44 to 8.33 compared to patients without diabetes [1, 2]. According to Dooley and Chaisson [1], as well as to Jeon and Murray [2], the possibility of developing tuberculosis among type 2 diabetes patients has been recognized through clinical and epidemiological studies [2]. It have been prove that type 2 diabetes is linked with the harshness of tuberculosis dpathology, touching at the same time the disease manifestations and the response to medication [1]. After all the clinical and epidemiological consequences of tuberculosis and diabetes, little data are available on the biochemical and immunological mechanisms of the susceptibility of TB to diabetes. The susceptibility of diabetes patients to tuberculosis

has been attributed to factors among which macrophage and lymphocyte function as well as hyperglycaemia and insulin resistance [3, 4]. Previous studies in patients having both diabetes tuberculosis have shown a reduction of proinflammatory cytokines [5, 6]. A study conducted by Kumar and collaborators in children suffering from tuberculosis reported a suppressed level of T helper type 1 (Th1), Treg, and type 17 (Th17) cytokine in active tuberculosis [7]. Kumar et al. [8] also reported in pulmonary tuberculosis associated with prediabetic patients a dysregulated cytokine response. Another study conducted by Kumar et al.[3] on diabetic and non-diabetic patients with tuberculosis, it was reported heightening systemic Th1, Th17, and other proinflammatory cytokines. The immune response orchestrated by the immune systems to tuberculosis infection, with Th1, Treg and Th17 cytokines family have been proved to be involved in protection against tuberculosis disease [2], whereas Treg and anti-inflammatory cytokines and type 1 IFNs have proved to be linked with elevated susceptibility to disease [8]. This study aimed to evaluate the impact of type 2 diabetes on pulmonary TB. To achieve this, we assessed the plasma concentration of Th1, Treg and Th17 cytokines among patients suffering simultaneously from tuberculosis and diabetes and compare them with those of patients suffering from pulmonary tuberculosis without diabetes.

## 2. METHODS

### 2.1. STUDY POPULATION

Our study was based on a group of 42 active pulmonary tuberculosis (TB) patients newly diagnosed at the Tuberculosis Reference Laboratory Bamenda North West Region of Cameroon. Among the 42 patients recruited in this study, 21 had diabetes and the other 21 without. The diagnosis of tuberculosis was through the sputum smear and positivity of the culture. The diagnosis of type 2 was done from American Diabetes Association [ADA] guidelines of fasting blood sugar [?] 126 mg/dl or 2-hours plasma glucose (PG) [?] 200 mg/dl but also glycated haemoglobin (HbA1c) cut-off point 6.5%. Fasting blood glucose was performed on capillary blood after overnight fasting (at least 10 hours without eating or smoking but can drink water during this period)[9]. Random blood sugar (RBS) level was measured using the OneTouch Ultra W glucometer from Johnson and Johnson Company, United Kingdom [9].. The 2h-PG was performed by giving 75 g anhydrous glucose dissolved in 200-300 ml of water to patients to be consumed within 5 minutes, followed by a further 100 ml of water; and capillary plasma glucose was measured after 2 hours [9]. Only those with apparently normal (fasting blood glucose level less than 99 mg/dL) glucose levels were subjected to the oral glucose tolerance test and patients were considered diabetic if two successive weeks' measurement of fasting blood glucose [?] 126 mg/dl or 2h-plasma glucose [?] 200 mg/dl [9]. In a patient with classic symptoms of hyperglycaemia tor hyperglycaemic crisis, only random plasma glucose and HbA1c were performed and the patient was considered diabetic if two successive weeks random plasma glucose [?] 200 mg/dl and HbA1c [?] 6.5% [9]. All the participants were HIV negative, were newly diagnosed and not under anti-tuberculosis treatment. No significant difference was observed in the two groups regarding the smear grades, thought the TB diabetes group presented a slightly high smear grade. Anthropometric parameters, among which, height, weight, and waist circumference; and biochemical parameters including blood glucose level, lipid profile and liver enzymes were obtained by standardized techniques as detailed by the International Federation of Clinical Chemistry and Laboratory Medicine [10]

### 2.2 DETERMINATION OF CIRCULATING CYTOKINES LEVELS

The concentration of plasma cytokines was determine using a ELISA cytokine assay system (Sino Biological Inc). Analysed parameters include IFN- $\gamma$ , Tumor necrosis factor (TNF)- $\alpha$ , IL-1 $\beta$ , IL-12, IL-4, IL-6, IL-10, IL-17A and IL-22.

### 2.3 STATISTICAL ANALYSIS

Continuous variables from subjects' characteristics and cytokines plasma concentration were express as means ( $\pm$  Standard Deviation) for parametric data and medians (Inter Quartile Ranges, IQR) for non-parametric data. Comparison between diabetic and non-diabetic sets of TB positive subjects was made using the t-test and non-parametric Mann-Whitney U test as appropriate for continuous variables, then correlations between glycated haemoglobin (Hb1Ac) and cytokines levels were done using Spearman "r" value. The level

of statistical significance was set at  $p < 0.05$ . Statistical analysis was performed using GraphPad version 8.0.2 Software, San Diego, California, USA.

## 2.4 ETHICAL CONSIDERATION

The ethical clearance was obtained from «Ethics Review and Consultancy Committee of Cameroon Bioethics Initiative (CAMBIN)» (CBI/294/ERCC/CAMBIN) and informed written and signed consent was obtained from each participant.

## 3. RESULTS

### 3.1 CHARACTERISTICS OF THE STUDY POPULATION

The characteristics of the study population include anthropometric, clinical and biochemical features are presented in Table 1 compared with patients with and those without diabetes. No significant difference was observed in anthropometric (Age (year)), Sex, M/F, BMI, kg/m<sup>2</sup> and Waist circumference) between TB patients with and without diabetes. Clinical parameters were found to be significantly high in TB with diabetes [fasting blood glucose ( $p < 0.0001$ ), 2hPG ( $p = 0.0097$ ) and glycated haemoglobin % ( $p < 0.0001$ )] compared to TB patients without diabetes. While with biochemical features, Total cholesterol ( $p = 0.0093$ ), Serum triglycerides ( $p = 0.0001$ ) and Low-density lipoprotein cholesterol ( $p = 0.0086$ ), were significantly high among TB with diabetes, whereas High-density lipoprotein cholesterol found to be significantly ( $p = 0.0002$ ) high among TB patients without diabetes. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma-glutamyltransferase ( $\delta$ GT) and Alanine aminotransferase (ALP) shows no significant differences between the two study populations.

### 3.2 IMPACT OF DIABETES ON THE SERUM CIRCULATING LEVEL OF TYPE 1, TREG AND TYPE 17 CYTOKINE

To evaluate the impact of type 2 diabetes on Th1, Treg and Th17 cytokines on tuberculosis, we determine the plasma concentration of interferon-gamma (IFN- $\gamma$ ), Tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL) namely: IL-1 $\beta$ , IL-12, IL-4, IL-6, IL-10, IL-17A and IL-22 in TB patients with and without diabetes (Figure 1). Figure 1, shows the geometric mean of circulating concentration of Th1 cytokines, namely IFN- $\gamma$  ( $794.5 \pm 326.2$  pg/ml vs.  $147.8 \pm 130.5$  pg/ml) and TNF- $\alpha$  ( $800.9 \pm 372.7$  pg/ml vs  $500.6 \pm 324.9$  pg/ml) to be highly important among diabetics compared to patients without diabetes. The plasma concentration of Treg cytokine IL-10 ( $160.7 \pm 81.03$  pg/ml vs  $68.2 \pm 67.72$  pg/ml) also found to highly increased in patients with diabetes compared to those without. Furthermore, the plasma concentration of Th17 cytokine IL-17A was found to be also significantly high among diabetes compared to non-diabetic patients with tuberculosis ( $229.0 \pm 187.4$  pg/ml vs  $105.7 \pm 108.4$  pg/ml). Contrary, IL-22 ( $7.09 \pm 3.538$  pg/ml vs  $22.720 \pm 2.278$  pg/ml) was found to be present at significantly lower concentration in patients with diabetes compared to those without. Thus, active pulmonary tuberculosis patients with diabetes are associated with high plasma concentration of IFN- $\gamma$  and TNF- $\alpha$ , Th17, IL-17A and Treg cytokines.

### 3.3 CORRELATION BETWEEN PLASMA CYTOKINES AND HBA1C CONCENTRATION

HbA1c is an accurate indicator of the level of diabetic control and high values reflect poor control of blood glucose level [11]. To evaluate the relationship between the plasma concentration of Th1, Th17 and Treg cytokines, with the level of diabetic complication, we determine the link of IFN- $\gamma$ , TNF- $\alpha$ , IL-6, IL-10, IL-17A, and IL-22 with HbA1c concentration in all the individuals in the study. As presented in Figure 2, the plasma concentration of IFN- $\gamma$ , TNF- $\alpha$ , IL-10, IL-17A, and IL-22 and IL-10 each shows an important positive association with the HbA1c concentration among TB patients. This was not the case with IL-6 where there was not associated with glycated haemoglobin.

### 3.4 INVERSE CORRELATION OF IFN- $\gamma$ AND IL-22 AMONG DIABETIC PATIENTS WITH INFLAMMATORY CYTOKINE PLASMA LEVELS

In the goal of discriminating Diabetic from non-diabetic TB positive individuals, the correlation between pro- and anti-inflammatory cytokines plasmatic levels was determined as shown in Figure 3. These data showed

a significantly increased association between IL-22 and IFN- $\gamma$  plasmatic levels ( $r=0.5150$ ;  $p=0.0005$ ).

#### 4. DISCUSSION

The immune components are altered in type 2 diabetes mellitus. Changes include specific cytokines, the activation process and state of immune cell subsets, as well as an increase of tissue apoptosis and fibrosis [12]. This may be since inflammation involve in the type 2 diabetes pathogenesis, but also how these affect the response to antigens remains unclear. It has been proved a diabetic patient are almost 3 times more likely to develop tuberculosis than a non-diabetic. The immunological basis for this susceptibility is not yet well understood. One possible explanation is dysglycaemia in which both diabetic and prediabetic impairs immune function and, in consequence, permits the primary infection or the reactivation of latent TB [13, 14]. According to Kumar and Babu (2017), immune responses against microbial pathogens in patients with diabetes are compromised, particularly in patients with chronic hyperglycemia [12]. The application of this to tuberculosis infection is not well-documented [15]. The infection outcome of host defence against mycobacterial infections is mediated mostly by cytokines among which IFN- $\gamma$  and TNF- $\alpha$  are of major importance for host defence against intracellular infection by activating cellular immunity to kill bacterial and infected cells [15, 16].

Newly recognized Th17 cells have provided new observation on important mechanisms in antimicrobial host defence including *M. tuberculosis* [17, 18], though the exact role of IL-17 in the *Mycobacterium tuberculosis* infection is still unclear. Our results on concomitant tuberculosis and diabetes patients show an important type of cytokine expression. Firstly, the expression of cytokines implicated in the protection against infection, namely IFN- $\gamma$ , TNF- $\alpha$ , IL-6, IL-10 and IL-17A, are all expressed at higher concentration in diabetics inpatients. Secondly, those not having a role in resistance, including IL-22, are present at much lower levels. The activation of Th17 cells results in a large production of inflammatory cytokines including 17A (IL-17A)/IL-17F, IL-21, IL-22 and IL-23, which are produced by Th17/Th22 cells or involved in their development(16) 17 and can also be produced by CD4+ T, CD8+ T,  $\gamma\delta$  T, natural killer T (NKT) and NK cell(19). IL-17A plays a critical role in preventing MTB infection through the induction of mature granuloma formation [19, 20]. IL-22 stimulates the secretion of antibacterial peptides, including  $\beta$ -defensins, lipocalin and islet-3- $\gamma$  regenerating from lung epithelial cells and monocytes and macrophages to destroy pathogens. In addition to this, IL-22 can activate macrophages to mediate mycobacterial control and induce TNF- $\alpha$  production [21]. Our study, therefore, suggests that in TB diabetes patients, the regulation of IL-17A is different compared to IL-22. However, cell-mediated immune responses are distorted in patients having resistance to insulin, which may point out T-cell factors are associated with insulin sensitivity imbalance. Surely, T cells having CD4+ markers also known as T cells CD4+ that produce IL-17A and IFN- $\gamma$  rise in magnitude and frequency and promote inflammation and produce several cytokines through Th1 or Th17 cells linked on resistance to insulin [22]. Moreover, type 2 diabetes has also been proven to lower natural regulatory T cells frequencies, demonstrating the imbalance of proinflammatory cytokines in type 2 diabetes patients [23]. Therefore, underlying needy diabetes controlled by itself could lead to an increase in Th1, Th2 and Th17 cytokines observed in TB diabetic patients. The increased production of Th1, Th2 and Th17 cytokines is linked with important plasma concentration of interleukin-1 family and other cytokines having proinflammatory activities. The pro-inflammatory cytokines IL-1 $\alpha$ , IL-1 $\beta$  and IL-18, are members of the IL-1 family. IL-1 $\alpha$  is important for resistance to infection, whereas, IL-12 also showed to produce a protective action against *Mycobacterium tuberculosis* [24]. Interleukin-6 (IL-6) is a pleiotropic cytokine produced in response to inflammatory stimuli and is involved in the essential cellular processes of differentiation, proliferation, and apoptosis [24]. It has been proven to intermediate in the inhibition of disease advancement [25]. The possible well work for the rise in baseline concentration of proinflammatory cytokines in patients with tuberculosis diabetes commodity could be both a decrease in the levels of plasma cytokines regulatory as shown by the decrease of plasma concentration of IL-4 and IL-10. Elsewhere, regulation of Treg cytokines are known to play a role in increasing touchiness to infection. Nevertheless, this study suggests that host protective cytokines do not expose to altered homeostasis production but are currently present in high concentrations in patients with tuberculosis and diabetes and are not linked to a decrease in the production of host protective cytokines proinflammatory.

## CONCLUSION

The baseline characteristics of anthropometric shows no significant difference between TB with diabetes and without diabetes. Clinical parameters were found to be significantly high in TB with diabetes compared to TB without diabetes, while some with biochemical features except for high-density lipoprotein cholesterol found to be significantly high among TB patients without diabetes, others found to be significantly high among TB patients with diabetes. Pulmonary TB with diabetes is linked with a high concentration of Th1 (IFN- $\gamma$  and TNF- $\alpha$ ), Th17 (IL-17A) and Treg cytokines. The plasma concentration of IFN- $\gamma$ , TNF- $\alpha$ , IL-10, IL-17A, and IL-22 and IL-10 exhibited each an important positive association with the HbA1c concentration in the TB patients except with IL-6 where there is no association with glycated haemoglobin. A significantly increased association was found between IL-22 and IFN- $\gamma$  plasmatic levels.

## Declaration

## Acknowledgements

We wish to thank all participants who sacrificed their time and donated blood samples for this study. We also thank all technicians of Tuberculosis Reference Laboratory Bamenda North West Region of Cameroon for their contributions.

## Disclosure

The authors declare that they have no competing interests.

## Author's contributions

LFS and CBT designed the study. LSF and OK performed the field data collection, TFT and OBN analyzed the data, LSF, IMA, STB wrote the manuscript; all the authors read and approved the final manuscript.

## Funding

The authors received no financial support for the research and writing of this manuscript.

## Provenance and peer review

Not commissioned; externally peer reviewed

## Data availability statement

No additional data that support this finding of this study is available.

## Author's information

1. LSF is a PhD in the Department of Biochemistry of the University of Dschang, Cameroon.
2. TFT is a PhD in the Department of Biochemistry of the University of Dschang, Cameroon.
3. OBN is a Lecturer in the Department of Biology of the University of Yaoundé
4. IMA is a Lecturer in the Department of Biochemistry of the University of Dschang
5. STB is a PhD in the Department of Biochemistry of the University of Dschang, Cameroon and Public School of Medical Laboratory Technicians, Yaoundé, Cameroon
6. OK is a PhD student in the Department of Biochemistry of the University of Dschang, Cameroon.

7. CBT is an Associate Professor of Immunology and Molecular Biology in the Department of Biochemistry of the University of Dschang in Cameroon and Head of Department of Biochemistry of the University of Bamenda, Cameroun

## References

1. Dooley KE, Chaisson RE: Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis* 2009; 9:737-746.
2. Jeon CY, Murray MB: Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. *PLoS Med* 2008; 5:e152.
3. Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Fay MP, Nutman TB, Babu S: Type 2 diabetes mellitus coincident with pulmonary tuberculosis is associated with heightened systemic type 1, type 17, and other proinflammatory cytokines. *Ann Am Thorac Soc* 2013; 10:441-449.
4. Martinez N, Kornfeld H: Diabetes and immunity to tuberculosis. *Eur J Immunol* 2014; 44:617-626.
5. Vallerskog T, Martens GW, Kornfeld H: Diabetic mice display a delayed adaptive immune response to *Mycobacterium tuberculosis*. *J Immunol* 2010; 184:6275-6282.
6. Restrepo BI, Fisher-Hoch SP, Pino PA, Salinas A, Rahbar MH, Mora F, Cortes-Penfield N, McCormick JB: Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. *Clin Infect Dis* 2008; 47:634-641.
7. Kumar NP, Anuradha R, Suresh R, Ganesh R, Shankar J, Kumaraswami V, Nutman TB, Babu S: Suppressed type 1, type 2, and type 17 cytokine responses in active tuberculosis in children. *Clin Vaccine Immunol* 2011; 18:1856-1864.
8. Kumar NP, Banurekha VV, Nair D, Sridhar R, Kornfeld H, Nutman TB, Babu S: Coincident pre-diabetes is associated with dysregulated cytokine responses in pulmonary tuberculosis. *PLoS One* 2014; 9:e112108.
9. Fonkeng LS, Ali IM, Noubom M, Bamou R, Sterve AHSR, Leo A, Kuiaite JR, Tume CB: Prevalence, Predictors and Treatment Outcome of Type 2 Diabetes among Newly Diagnosed Sputum Positive Pulmonary Tuberculosis Patients in Western Cameroon. *J Infect Dis Epidemiol* 2017; 3:1-13.
10. Rodriguez-Saldana J: The Diabetes Textbook : Clinical Principles, Patient Management and Public Health Issues, 1st ed. 2019. edn: Cham : Springer International Publishing : Imprint: Springer; 2019.
11. Kumar NP, Banurekha VV, Nair D, Kumaran P, Dolla CK, Babu S: Type 2 diabetes - Tuberculosis co-morbidity is associated with diminished circulating levels of IL-20 subfamily of cytokines. *Tuberculosis (Edinb)* 2015; 95:707-712.
12. Kumar Nathella P, Babu S: Influence of diabetes mellitus on immunity to human tuberculosis. *Immunology* 2017; 152:13-24.
13. Ponce-De-Leon A, Garcia-Garcia Md Mde L, Garcia-Sancho MC, Gomez-Perez FJ, Valdespino-Gomez JL, Olaiz-Fernandez G, Rojas R, Ferreyra-Reyes L, Cano-Arellano B, Bobadilla M *et al* : Tuberculosis and diabetes in southern Mexico. *Diabetes Care* 2004; 27:1584-1590.
14. Ayelign B, Negash M, Genetu M, Wondmagegn T, Shibabaw T: Immunological Impacts of Diabetes on the Susceptibility of *Mycobacterium tuberculosis*. *J Immunol Res* 2019; 2019:6196532.
15. Al-Attayah RJ, Mustafa AS: Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and *Mycobacterium bovis* bacilli Calmette-Guerin (BCG)-vaccinated healthy subjects. *Clin Exp Immunol* 2009; 158:64-73.
16. Li Y, Wei C, Xu H, Jia J, Wei Z, Guo R, Jia Y, Wu Y, Li Y, Qi X *et al* : The Immunoregulation of Th17 in Host against Intracellular Bacterial Infection. *Mediators Inflamm* 2018; 2018:6587296.

17. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol* 2005; 6:1123-1132.
18. Stockinger B, Veldhoen M, Martin B: Th17 T cells: linking innate and adaptive immunity. *Semin Immunol* 2007; 19:353-361.
19. Shen H, Chen ZW: The crucial roles of Th17-related cytokines/signal pathways in *M. tuberculosis* infection. *Cell Mol Immunol* 2018; 15:216-225.
20. Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, Kishihara K, Hara H, Nakae S, Iwakura Y, Matsuzaki G: Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. *J Immunol* 2010; 184:4414-4422.
21. Guillon A, Jouan Y, Brea D, Gueugnon F, Dalloneau E, Baranek T, Henry C, Morello E, Renauld JC, Pichavant M *et al* : Neutrophil proteases alter the interleukin-22-receptor-dependent lung antimicrobial defence. *Eur Respir J* 2015; 46:771-782.
22. Xia C, Rao X, Zhong J: Role of T Lymphocytes in Type 2 Diabetes and Diabetes-Associated Inflammation. *J Diabetes Res* 2017; 2017:6494795.
23. Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Nutman TB, Babu S: Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. *J Infect Dis* 2013; 208:739-748.
24. Domingo-Gonzalez R, Prince O, Cooper A, Khader SA: Cytokines and Chemokines in *Mycobacterium tuberculosis* Infection. *Microbiol Spectr* 2016; 4.
25. Martinez AN, Mehra S, Kaushal D: Role of interleukin 6 in innate immunity to *Mycobacterium tuberculosis* infection. *J Infect Dis* 2013; 207:1253-1261.


**Table 1.** Anthropometric and biochemical parameters of TB-DM and TB without DM

Charactéristiques	TB-DM	TB-NDM	P-value
	(n = 21)	(n = 21)	
Age (year)	46.76±2.789	46.95±2.816)	0.9619
Sex, M/F	10/11	11/10	0.9999
BMI, kg/m <sup>2</sup>	19.81±0.9611	20.19±1.027	0.7882
Waist circumference	79.29±2.014	80.29±2.240	0.7417
Fasting blood glucose (mg/dl)	10.52±0.9521	5.70±0.1721	<0.0001
2h-PG (mg /dl)	11.30±1.815	6.88±0.3133	0.0097
HbA1c (%)	12.42±1.678	4.265±2.221	<0.0001
Total cholesterol (mg/dl)	157 (132–198)	131 (109–198)	0.0093
Serum triglycerides (mg/dl)	143 (56–398)	48 (26–317)	0.0001
HDL cholesterol (mg/dl)	39 (32–63)	49 (28–70)	0.0002
LDL cholesterol (mgdl)	109 (51–162)	92 (42–136)	0.0086
ASAT (U/l)	247.6 (7.2-73,5)	239.8 (3.3-30.4)	0.8813
ALAT (U/l)	379.8 (43.8-486,9)	325.5 (108.1-633,5)	0.5499
γ-GT (U/l)	379.8 (43.8-486,9)	325.5 (108.1-633.5)	0.8178
ALP (U/l)	64.79 (221.8-616)	31.71 (177.2-691.3)	0.2403

2h-PG = 2hours plasma glucose; ALP = Alkaline phosphatase; ALAT = Alanine aminotransferase; ASAT = Aspartate aminotransferase; BMI = Body mass index; γ-GT = Gamma glutamyl transferase; M/F = male/female; HbA1c = Glycated hemoglobin; HDL = High density lipoprotein; LDL = Low density lipoprotein; OGTT = Oral glucose tolerant test; TB-DM = Tuberculosis with diabetes mellitus; TB-NDM =



Tuberculosis without diabetes mellitus.



**Figure 1.** Circulating levels of T helper type 1, Treg and type 17 cytokines.

TB-DM = Tuberculosis with diabetes mellitus; TB-NDM = Tuberculosis without diabetes mellitus. IFN- $\gamma$  = Interferon gamma; TNF- $\alpha$  = Tumor Necrosis factor alpha; IL-1 $\beta$  = Interleukine-1 Beta; IL-12 = Interleukine-12; IL-4 = Interleukine-4; IL-6 = Interleukine-6; IL-10 = Interleukine-10; IL-17 = Interleukine-17; IL-22 = Interleukine-22; Th1 = Type 1 helper T-cells; Treg = regulatory T-cells; Th17 = Type 17 helper T-cells

**Figure 2 .** Correlation between plasma concentration of cytokines and glycated hemoglobin (HbA1c) concentrations in TB patients.

**Figure 3 .** The supply of IFN- $\gamma$  and IL-22 on the discrimination TB diabetics to TB non diabetics patients